Phase III clinical trial - Sein métastatique RH+

DESTINY-Breast06 (D9670C00001)
Sein métastatique RH+
Ouvert depuis le: 12.08.2021
Site: Paris
Ouvert depuis le: 05.20.2021
Site: Saint-Cloud
Public cible
TITLE PAGE;A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus InvestigatorÀs Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Description de l'essai

This is a study of trastuzumab deruxtecan, which was approved by the FDA (in December 2019) for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens.;Participants will receive this study drug along with a cancer drug, an immune checkpoint inhibitor, anti-PD1, called nivolumab.;The study will be done in two parts:;ÀPart 1 is to identify the recommended dose to use for treatment.;ÀPart 2 is to find out how well the combination works, and how safe and tolerable it is